^
Association details:
| Biomarker: | PRO-C3 elevation |
|---|---|
| Cancer: | Hormone Receptor Positive Breast Cancer |
| Drug: | Keytruda (pembrolizumab) (PD1 inhibitor) |
| Direction: | Resistant |
Evidence:
Source:
Title:
Clinical value of noninvasive biomarkers reflecting a collagen-rich stroma in metastatic melanoma patients treated with anti-PD1 therapy.
Published date:
05/13/2020
Excerpt:
The median overall survival was 417 and 511 days in biomarker high patients compared to 1269 and 1269 days in biomarker low patients, for PRO-C3 and PC3X, respectively.
DOI:
10.1200/JCO.2020.38.15_suppl.3049
